Full bibliography — 80+ peer-reviewed outputs across nephrology, AI, and clinical medicine.

IgA Nephropathy

Chronic Kidney Disease, Proteinuria & Haematuria

IgA Nephropathy & Henöch-Schonlein purpura

Glomerular frontiers: consensus perspectives from GlomCon Hawaii 2025

IgA Nephropathy: a paradigm shift in treatment strategies

IgA Nephropathy: an overview of the clinical trials

The pathogenesis of IgA nephropathy and implications for treatment

IgA Nephropathy: Emerging mechanisms of Disease

Primary IgA Nephropathy: new insights and emerging therapies

A review of focal segmental glomerulosclerosis classification with a focus on genetic associations

Technological Innovations to Improve Patient Engagement in Nephrology

Novel Treatment Paradigms: Primary IgA Nephropathy

IgA nephropathy: an overview of drug treatments in clinical trials

Clinical application of microRNAs in glomerular diseases

Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link

New insights into the pathogenesis and treatment strategies in IgA nephropathy

Managing Crescentic IgA Nephropathy

The non-coding RNA landscape in IgA nephropathy – where are we in 2021?

Monitoring immune responses in IgA Nephropathy: biomarkers to guide management

New Strategies and Perspectives on Managing IgA Nephropathy

IgA Nephropathy: Driving innovation with a rare renal disease registry

MicroRNAs: A new avenue to understand, investigate and treat IgA Nephropathy?

Timing of peritoneal dialysis catheter insertion: an analysis of eGFR and KFRE thresholds for insertion referral

Characterization of Patient-Reported Loin Pain in IgAN

B cell derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy

Distinct neutralising and complement-fixing antibody responses can be induced to the same antigen in haemodialysis patients after immunisation with different vaccine platforms

Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis

Risk Factors associated with COVID-19 severity among patients on maintenance haemodialysis: a retrospective multi-centre cross-sectional study

Regional variations in nephrology trainee confidence with clinical skills may relate to the availability of local training opportunities in the UK; results from a national survey

Burnout and Long COVID among the UK nephrology workforce: results from a national survey investigating the impact of COVID-19 on working lives

A pilot study to predict risk of IgA nephropathy progression based on miR-204 expression

An ethnic variation in the acceptance of biologic disease modifying therapies: a university hospital experience

Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving haemodialysis: a call to arms

Macrophage interactions with collecting duct epithelial cells are capable of driving tubulointerstitial inflammation and fibrosis in IgA Nephropathy

Acoustic Trauma slows AMPAR-mediated EPSCs in the auditory brainstem reducing GluA4 subunit expression as a mechanism to rescue binaural function

Acute respiratory distress syndrome driven by severe hypercalcaemia and acute kidney injury: a case report and literature review of a rare, life threatening complication

Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis associated nephritis

Diabetic myonecrosis: a case series of two dialysis-dependent patients

High dose oral linezolid achieved rapid clinical and microbiological recovery in a severely overweight male with long standing infected ulcers

Microangiopathic haemolytic anaemia in a young female

Should histology guide treatment decisions in IgA nephropathy?

The COVID-19 vaccination and IgA Nephropathy: Further cause for reassurance

The mucosal microbiome and IgA nephropathy: a new target for treatment?

Dynamic individualized risk prediction in IgA nephropathy: entering the era of artificial intelligence

Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?

Impact of the COVID-19 pandemic on training, morale and well-being amongst the UK renal workforce

The Exclusion of patients with chronic kidney disease in prospectively registered interventional trials for COVID-19. A Rapid review of international registry data

View from here: Prescribing Skills Assessment

View from here: Smart Phones & Medical Education

The importance of counseling in young, female epileptic patients

Loin pain in rare kidney disease: analysis of 3867 questionnaire responses with linked data from the UK national registry of rare kidney diseases (RaDaR)

Exploring the impact of loin pain in IgA nephropathy: a UK wide mixed-methods qualitative study

Towards an IgA nephropathy atlas

#715 Loin pain in adults with IgA nephropathy: insights from qualitative interviews with patients, families, and healthcare professionals

Toward Consensus on Glomerular Disease Centers of Excellence: Results from a Delphi Panel Study: SA-PO0794

Can artificial intelligence predict the need for acute renal replacement therapy among inpatients with acute kidney injury?

Digital spatial profiling can be used to study glomerular endothelial cells in IgA Nephropathy

WCN23-0066 Identifying druggable pathways in IgA nephropathy using spatial transcriptomics

WCN23-0139 Leveraging modern machine learning tools to predict outcomes of in-patient acute kidney injury

Can artificial intelligence predict the need for acute renal replacement therapy among in-patients with acute kidney injury?

Macrophage derived products induce pro-inflammatory and pro fibrotic responses in renal collecting ducts: A potential role in the pathogenesis of IgA nephropathy?

Is there an ethnic variation in the acceptance of biologic therapy among patients with axial spondyloathropathy? A university hospital experience

Ethnic Variation in the acceptance of biologic therapy among rheumatology patients - a university hospital experience

Outcomes from the International Society of Nephrology Forum on Complement Therapeutics in C3GN and IgAN

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR registry

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active controlled, phase 3 trial

Sparsentan versus irbesartan in focal segmental glomerulosclerosis

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Sparsentan in patients with IgA nephropathy; a pre-specified interim analysis from a randomised, double-blind, active-controlled clinical trial

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

IgA nephropathy patient baseline characteristics in the Sparsentan PROTECT study

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY):

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY):

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY):

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY)

Effect of Hydroxychloroquine in hospitalised patients with COVID-19

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY)

Dexamethasone in hospitalised patients with COVID-19: preliminary report